Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective-Reference-Cited by-同舟云学术

Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective

Published:2023-11-20 Issue:2 Volume:42 Page:133-136
ISSN:1170-7690
Container-title:PharmacoEconomics
language:en
Short-container-title:PharmacoEconomics

Author:

Orozco-Leal Giovany^ORCID,Johnson Eugenie Evelynne^ORCID,Hosseinijebeli Sedighe^ORCID,Robinson Tomos^ORCID,Homer Tara^ORCID,Eastaugh Claire H.^ORCID,Richmond Catherine^ORCID,Tanner Louise,Meader Nick,Kenny Ryan^ORCID,Wallace Sheila A.^ORCID,Rice Stephen^ORCID

Funder

Health Technology Assessment Programme

Publisher

Springer Science and Business Media LLC

Subject

Public Health, Environmental and Occupational Health,Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s40273-023-01328-w.pdf

Reference19 articles.

1. Latimer N. NICE DSU Technical Support Document 14: Undertaking survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data. Updated March 2013. Sheffield: University of Sheffield; 2011. https://www.sheffield.ac.uk/nice-dsu/tsds/survival-analysis.

2. Rutherford M, Lambert P, Sweeting M, Pennington R, Crowther M, Abrams K, Latimer N. NICE DSU technical support document 21: flexible methods for survival analysis [TSD21]: Decision Support Unit, ScHARR, University of Sheffield; 2020. http://www.nicedsu.org.uk.

3. National Institute for Health and Care Excellence (NICE). Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer [TA876]. London: National Institute for Health and Care Excellence (NICE); 2023. https://www.nice.org.uk/guidance/ta876.

4. Bristol Myers Squibb Pharmaceuticals Ltd. Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small cell lung cancer [ID3757]. Document B. Company evidence submission—original submission received on 23 September 2022. Bristol Myers Squibb Pharmaceuticals; 2022.

5. Filleron T, Bachelier M, Mazieres J, Pérol M, Meyer N, Martin E, et al. Assessment of treatment effects and long-term benefits in immune checkpoint inhibitor trials using the flexible parametric cure model: a systematic review. JAMA Netw Open. 2021;4(12):e2139573-e. https://doi.org/10.1001/jamanetworkopen.2021.39573.